Welcome to LookChem.com Sign In|Join Free
  • or
MPEG6-CH2CH2COOH, also known as m-PEG7-acid, is a monodisperse polyethylene glycol (PEG) linker with a terminal carboxylic acid group. The carboxylic acid group is stable and can be activated, allowing it to react with primary amine groups in the presence of activators such as EDC or HATU to form stable amide bonds. The hydrophilic PEG spacer increases solubility in aqueous media.

874208-91-0

Post Buying Request

874208-91-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

874208-91-0 Usage

Uses

Used in Bioconjugation:
MPEG6-CH2CH2COOH is used as a PEG linker for bioconjugation, providing a stable and hydrophilic spacer between biomolecules and their conjugates. This enhances the solubility and stability of the conjugated biomolecules in aqueous media.
Used in Drug Delivery:
MPEG6-CH2CH2COOH is used as a component in drug delivery systems, where it can be used as a carrier for therapeutic agents. The PEG spacer improves the solubility and bioavailability of the drug, while the carboxylic acid group allows for stable attachment of the drug to the PEG linker.
Used in PEG Hydrogel:
MPEG6-CH2CH2COOH is used as a crosslinker in the formation of PEG hydrogels. The carboxylic acid group can react with other PEG molecules or with amine-containing molecules to form stable hydrogels with tunable properties.
Used in Surface Functionalization:
MPEG6-CH2CH2COOH is used for surface functionalization, where it can be attached to various surfaces to provide a hydrophilic and biocompatible coating. The carboxylic acid group allows for covalent attachment to surfaces containing amine or other reactive groups.
Used in Crosslinking:
MPEG6-CH2CH2COOH is used as a crosslinking agent in various applications, such as in the formation of polymer networks or in the conjugation of multiple molecules. The carboxylic acid group can react with primary amine groups to form stable amide bonds, enabling the crosslinking of molecules or the formation of stable structures.

Check Digit Verification of cas no

The CAS Registry Mumber 874208-91-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,4,2,0 and 8 respectively; the second part has 2 digits, 9 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 874208-91:
(8*8)+(7*7)+(6*4)+(5*2)+(4*0)+(3*8)+(2*9)+(1*1)=190
190 % 10 = 0
So 874208-91-0 is a valid CAS Registry Number.

874208-91-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 3-{2-[2-(2-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-propionic acid

1.2 Other means of identification

Product number -
Other names 4,7,10,13,16,19,22-Heptaoxatricosanoic acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:874208-91-0 SDS

874208-91-0Relevant academic research and scientific papers

PEPTIDIC LINKERS AND CRYPTOPHYCIN CONJUGATES, USEFUL IN THERAPY, AND THEIR PREPARATION

-

Page/Page column 184; 185, (2018/12/02)

The present disclosure relates to compounds of formula (I): RCG1-L-P (I) wherein RCG1 represents a reactive chemical group being reactive towards a chemical group present on a polypeptide such as an antibody; P represents H, OH or an activated O; and L represents a specific linker. The disclosure also relates to cryptophycin payloads, as well as to cryptophycin conjugates, to compositions containing them and to their therapeutic use, especially as anticancer agents. The disclosure also relates to the process for preparing these conjugates.

Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof

-

Page/Page column 31, (2008/06/13)

Fatty acid compositions for administration of of pharmaceutical agents, such as proteins and peptides, protein and peptide conjugates, and/or cation-polypeptide conjugate complexes. In particular, the invention provides a solid pharmaceutical composition

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 874208-91-0